Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q2 FY25 results · Jul–Sep 2024
Emcure Pharmaceuticals reported revenue from operations of ₹2,001.98 crore and net profit of ₹201.55 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,001.98 | — | — | 1,815.14 | +10.3% |
| Other income | 35.65 | — | — | 23.44 | +52.1% |
| Total income | 2,037.64 | — | — | 1,838.58 | +10.8% |
| Profit before tax | 273.41 | — | — | 207.41 | +31.8% |
| Net profit for the period | 201.55 | — | — | 152.59 | +32.1% |
| Attributable to shareholders of the company | 194.57 | — | — | 144.08 | +35.0% |
| EPS, basic (₹) | 10.33 | — | — | 7.95 | +29.9% |
| Net margin (%) | 10.1 | — | 8.4 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,104.63 | — | — | 970.29 | +13.8% |
| Other income | 54.93 | — | — | 32.51 | +69.0% |
| Total income | 1,159.56 | — | — | 1,002.80 | +15.6% |
| Profit before tax | 119.36 | — | — | 55.05 | +116.8% |
| Net profit for the period | 86.92 | — | — | 40.45 | +114.9% |
| EPS, basic (₹) | 4.62 | — | — | 2.23 | +107.2% |
| Net margin (%) | 7.9 | — | 4.2 |
Consolidated
- Filed with BSE
- 08 Nov 2024, 14:11 IST
- Board meeting
- 07 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2024, 14:11 IST
- Board meeting
- 07 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE